Title
Impact of pre-diagnosis awareness of HIV-related stigma and dispositional coping on linkage to HIV care among newly diagnosed HIV+ Peruvian patients
Date Issued
03 July 2019
Access level
open access
Resource Type
journal article
Author(s)
Publisher(s)
Routledge
Abstract
A substantial body of literature has characterized how psychosocial factors, including HIV-related stigma and coping, are associated with HIV testing and HIV care utilization post-diagnosis. Less is known about if certain psychosocial characteristics pre-diagnosis may also predict linkage to care among individuals who receive an HIV-positive diagnosis. We examined if pre-diagnosis awareness/perception about HIV-related stigma and dispositional coping styles predicted linkage to HIV care within three months post-diagnosis with a secondary analysis of 604 patients from a randomized controlled trial (Sabes Study). Awareness/perception about HIV-related stigma, dispositional maladaptive and adaptive coping were measured before patients underwent an HIV test. Linkage to care was measured as receipt of care within three months of receiving the diagnosis. After adjusting for covariates, individuals who reported greater dispositional maladaptive coping pre-diagnosis had lower odds of linking to care, OR = 0.82, 95%CI [0.67, 1.00], p =.05. There was also a non-significant inverse association between dispositional adaptive coping pre-diagnosis and linkage to care. These preliminary data suggest the need for further longitudinal research and highlight the potential utility of pre-diagnosis psychosocial assessment and tailored counseling when providing positive HIV diagnosis results.
Start page
848
End page
856
Volume
31
Issue
7
Language
English
OCDE Knowledge area
Enfermedades infecciosas
Scopus EID
2-s2.0-85059688612
PubMed ID
Source
AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV
ISSN of the container
09540121
Sponsor(s)
This study was funded by National Institute on Drug Abuse [RO1 DA032106; PI: Ann Duerr]. Dr. Molina’s efforts were supported by the National Cancer Institute [grant numbers: K01CA193918 and R25CA092408]. This research was supported by an International Pilot Award made to Dr. De la Grecca from the University of Washington Center for AIDS Research (CFAR), an NIH funded program [P30AI027757] which is supported by the following NIH Institutes and Centers (NIAID, NCI, NIMH, NIDA, NICHD, NHLBI, NIA). We thank Mr. Wesley Peart for technical editing. We acknowledge ART drug donation from Gilead Sciences Inc. and Merck & Co Inc.
Sources of information: Directorio de Producción Científica Scopus